AKTSAktis Oncology, Inc.

$18.14

$15.1952 weeks$31.15

Price

End-of-day closes, not the intraday tick.

The five questions

2 of 5 available

Only two of the five can be answered for AKTS today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.

Is the business good?not enough filed
Is it safe?Mixed
Is the price fair?not enough filed
Is it growing?not enough filed
What is the market doing?Mixed

What they do

We are a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The field of targeted radiopharmaceuticals is currently led by two marketed products that illustrated transformative survival outcomes and quality of life benefits can be conferred by delivering radioisotopes to solid tumors.

In the company’s own words · 10-K filed Mar 30, 2026 · SEC EDGAR

P/En/a

Market value$1.72B

1 yearn/a

5 yearsn/a

Charts

As reported to the SEC, without any scoring.

Aktis Oncology, Inc. (AKTS) reported revenue of $3.4M in Q2 2026 (quarter ended Jun 30, 2026), up 134% from the same quarter a year earlier. That came with net loss of $24M. The next results filing is expected around Nov 12, 2026, a quarter after the last one.

What the company said

The company's own words from its current reports to the SEC, newest first

Aug 13, 2026Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026.Earnings release · press release
May 11, 2026Aktis Oncology Reports Financial Results and Business Highlights For First Quarter 2026.Earnings release · press release
Apr 16, 2026Appointment of Glenn Gormley to the Board of Directors On April 15, 2026, the board of directors (the “Board”) of Aktis Oncology, Inc. (the “Company”) appointed Glenn Gormley, MD, PhD as a Class I director of the Company, effective immediately.Director or officer change · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.

Biotechnology

The closest names by size in the same industry

Bicara Therapeutics Inc.